文献速递妇科

阴道子宫悬吊术与阴道子宫切除术联合顶端悬吊术治疗盆腔器官脱垂的比较:一项5年成本-效果马尔可夫模型

Vaginal hysteropexy compared with vaginal hysterectomy with apical suspension for the treatment of pelvic organ prolapse: A 5-year cost-effectiveness Markov model.
PubMed 文献 · BJOG · 2023-09-05

本研究采用决策分析马尔可夫模型,模拟健康子宫脱垂女性接受经阴道子宫悬吊术(HP)或阴道子宫切除术(VH)联合顶端悬吊术的5年成本-效果。结果显示,在每质量调整生命年(QALY)10万美元的支付意愿阈值下,HP-SS与HP-US均具成本-效果,VH-US与VH-SS均为劣势策略;HP-US为最优策略,但其优势随脱垂复发和再次手术概率增加而指数衰减。

要点

  • 在每QALY 10万美元支付意愿阈值下,HP-SS与HP-US两种子宫悬吊术式均具成本-效果。
  • HP-US相比HP-SS的增量成本-效果比(ICER)为90 738.14美元。
  • VH-US与VH-SS均为劣势策略;成本-效果可接受曲线在支付意愿阈值达9万至10万美元前支持骶棘韧带子宫悬吊术。

核心结论

  • 子宫悬吊术式是治疗子宫脱垂具成本-效果的经阴道手术方式。
  • 当子宫悬吊失败后脱垂复发和再次手术概率增加时,阴道子宫切除术联合顶端悬吊术变得更具成本-效果。
  • 鉴于文献中脱垂复发率的变异性,需要更多比较研究来理解不同术式间的成本-效果关系。

研究设计与样本

  • 决策分析模型评估5年时间跨度内的成本-效果,使用TreeAge®软件构建。
  • 对接受子宫脱垂手术的健康女性进行马尔可夫模型模拟,模拟脱垂复发、手术失败后再次手术及并发症率。
  • 进行了基础病例分析、敏感性分析和概率建模。

主要发现

  • HP-SS与HP-US在每QALY 10万美元支付意愿阈值下均具成本-效果。
  • HP-US相比HP-SS的ICER为90 738.14美元;VH-US与VH-SS均为劣势策略。
  • HP-US为最优成本-效果策略,但其优势随子宫悬吊失败后脱垂复发概率和再次手术需求增加而指数衰减。
  • 成本-效果可接受曲线在支付意愿阈值达9万至10万美元前支持骶棘韧带子宫悬吊术。

关键数值与推荐

  • 主要结局指标为增量成本-效果比(ICER)小于每QALY 10万美元。
  • HP-US相比HP-SS的ICER为90 738.14美元。
  • VH-US与VH-SS均为劣势策略。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出文献中脱垂复发率存在变异性,需要更多比较研究来理解不同术式间的成本-效果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to perform a 5-year cost-effectiveness analysis of transvaginal hysteropexy (HP) via sacrospinous ligament fixation (SS) or uterosacral ligament suspension (US) versus vaginal hysterectomy (VH) with apical suspension via sacrospinous ligament fixation (SS) or uterosacral ligament suspension (US) for the treatment of uterine prolapse. DESIGN: A decision analytic model assessed the cost-effectiveness of the surgical intervention over a 5-year horizon. SETTING: This model was constructed using TreeAge® software. POPULATION OR SAMPLE: Healthy women undergoing surgery for uterine prolapse were modeled. METHODS: A Markov model was constructed to simulate the possible recurrence of prolapse. Recurrence rates, repeat surgery for surgical failures and complication rates were modeled. Base case, sensitivity analyses and probabilistic modeling were performed. MAIN OUTCOME MEASURES: The primary outcome was the incremental cost-effectiveness ratio (ICER) of <$100 000 per quality-adjusted life year (QALY). RESULTS: Using the available prolapse recurrence rates and repeat surgery rates in the literature, both HP-SS and HP-US are cost-effective at a willingness-to-pay (WTP) threshold of <$100 000 per QALY. The incremental cost-effectiveness ratio (ICER) for HP-US compared to HP-SS is $90 738.14, while VH-US and VH-SS are both dominated strategies. HP-US is the optimal cost-effective strategy but decays exponentially with increasing probability of prolapse recurrence and need for repeat surgery after failed hysteropexy. The cost-effectiveness acceptability curve (CEAC) favors sacrospinous hysteropexy until reaching a WTP threshold between $90 000 and $100 000. CONCLUSION: Hysteropexy surgical strategies are cost-effective transvaginal surgical approaches for uterine prolapse. Vaginal hysterectomy with apical suspension becomes more cost-effective with increasing probability of prolapse recurrence and need for repeat surgery after failed hysteropexy. Given the variability of prolapse recurrence rates in the literature, more comparative studies are needed to understand the cost-effectiveness relationship between these different surgical approaches.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Wallace SL, Syan R, Lee K, et al. Vaginal hysteropexy compared with vaginal hysterectomy with apical suspension for the treatment of pelvic organ prolapse: A 5-year cost-effectiveness Markov model. BJOG. 2023. PMID: 37667669. doi:10.1111/1471-0528.17642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。